Biomark Diagnostics Inc. (CSE:BUX)

Market Cap	19.27M
Revenue (ttm)	155.03K
Net Income (ttm)	-1.90M
Shares Out	n/a
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,550
Average Volume	4,830
Open	0.2500
Previous Close	0.2600
Day's Range	0.2500 - 0.2500
52-Week Range	0.1800 - 0.3150
Beta	-0.62
RSI	65.14
Earnings Date	Jul 25, 2025

About Biomark Diagnostics

Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2014
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BUX

Financial Performance

In 2023, Biomark Diagnostics's revenue was 163,220, an increase of 6.34% compared to the previous year's 153,492. Losses were -1.43 million, -22.52% less than in 2022.